Business Wire

Philips launches new audio recorder range

Del

Speech Processing Solutions, the global no.1 in professional dictation now offers its Voice Tracer customers 8 GB internal memory space, doubling the recording time of its previous models.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160816005027/en/

Philips Voice Tracer audio recorder (Photo: Business Wire)

Philips Voice Tracer audio recorder (Photo: Business Wire)

The Philips Voice Tracers are the ideal consumer products for capturing spontaneous ideas, notes, conversations, lectures, interviews and meetings or music. “Recording applications on smartphones cannot compete with the crystal-clear audio quality and the battery life of our voice recorders. Our customers now benefit from an even higher internal storage capacity and thanks to the USB connection, they can even use the device as an external storage unit,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.

What makes Philips Voice Tracers unique?

The Philips Voice Tracer range is designed to offer outstanding audio recording results in every situation. The two built-in stereo microphones in the Voice Tracer for notes ( DVT2510/2710), are designed to deliver clear voice recordings and reduce background noise, even in loud environments. The DVT2710 comes with the latest Dragon NaturallySpeaking speech recognition software from Nuance already included, which transforms your audio recordings into a written document. The AutoAdjust+ function of the Voice Tracer for conversations (DVT4010) has been specially developed for constantly changing environments. It helps to greatly reduce unwanted background noise and adjusts the appropriate sound parameters automatically, perfect when recording more than one person at a time. The innovative 3Mic AutoZoom+ technology in the Voice Tracer for lectures and interviews (DVT6010) suppresses surrounding noises, while zooming in on the speaker’s voice, creating crystal clear recordings. For music enthusiasts, the new Voice Tracer DVT7500 offers 3Mic High-Fidelity, which allows you to capture music in its fullest dimension. Thanks to the XLR connections (XLR3), the new device offers a complete set of connections to ensure best audio recording quality for your music. And even for recording meetings, there is a perfect recorder. The Voice Tracer for meetings (DVT8010) with its 360° meeting microphone captures all speakers from every angle and guarantees a crystal-clear sound – even for meetings with more than five participants.

Best value for money

With its Voice Tracer range Philips delivers excellent quality with best value for money. Philips Voice Tracers are the ideal support tool for pupils and students, singers and songwriters, journalists and any small to middle-sized enterprise. No matter if they are used as learning aids, as support for creating new songs, for recording meetings or simply for capturing spontaneous thoughts like today’s shopping list, Philips Voice Tracers are suitable for every situation.

Speech-to-text option included

Philips SpeechLive is the optimal solution for those who want to turn their recordings into written documents. The cloud-based dictation workflow solution includes on-demand speech recognition software in over 20 different languages and a transcription service, where trained typists type up users’ recordings. Philips now offers a one-month free trial of the new service.

To find out more about the current products, please visit: www.dictation.philips.com/voice_recorders

Regional availability of models may differ.

About Speech Processing Solutions

Speech Processing Solutions is the global leader in professional dictation solutions. The company was founded in 1954 in Austria as a Philips subsidiary, and has been a driving force for innovative speech-to-text solutions for 60 years. The company developed ground-breaking products such as the mobile Philips SpeechAir, the Philips Pocket Memo voice recorder, the Philips SpeechMike Premium USB dictation microphone and the Philips Dictation Recorder app for smartphones, thus meeting its demands for excellence and superior quality. Thanks to the newest innovation, Philips SpeechLive, dictations and recordings will become faster and easier than ever before with a Cloud-based workflow services. Speech Processing Solution’s perfectly tailored offers and products help professionals save time and resources and maximize efficiency.

Connect with Speech Processing Solutions on:

Facebook: http://www.facebook.com/philipsvoicetracer

Instagram: https://www.instagram.com/philips_dictation/

Twitter @speech_com: http://www.twitter.com/speech_com

YouTube: http://www.youtube.com/philipsdictation

LinkedIn: http://www.linkedin.com/company/speech-processing-solutions

Contact information

Speech Processing Solutions
Christina Angerer
christina.angerer@speech.com
Tel: +43 1 60529-1488
www.philips.com/dictation

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom